Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn vitamin d2
learn TDM-105795
learn Greyverse
Research
5 / 1000+ results
research ER71/ETV2 Promotes Hair Regeneration from Chemotherapeutic Drug-Induced Hair Loss by Enhancing Angiogenesis
The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.
research Small molecules and small molecule drugs in regenerative medicine
Small molecule drugs show promise for advancing regenerative medicine but still face development challenges.
research Bioactive Molecules for Skin Repair and Regeneration: Progress and Perspectives
Bioactive molecules show promise for improving skin repair and regeneration by overcoming current challenges with further research.
research ELL Facilitates RNA Polymerase II–Mediated Transcription of Human Epidermal Proliferation Genes
ELL is crucial for gene transcription related to skin cell growth.
research Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets
Lymphatic vessels are essential for health and can be targeted to treat various diseases.
Community Join
5 / 1000+ resultscommunity Eirion ET-02( RS 5441) managed to defeat rodents, finally
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
community ET-02 Now Recruiting in Texas for Phase 1
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.